Results 81 to 90 of about 4,256 (179)

SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
SGLT2 inhibitors improve heart failure outcomes through integrated cardiorenal mechanisms. In the kidney, they reduce glucose and sodium reabsorption, promoting natriuresis, osmotic diuresis and renal protection. In the heart, they enhance myocardial energetics, reduce inflammation, oxidative stress, fibrosis and adverse remodelling, resulting in fewer
Jelica Grujic‐Milanovic, Jovana Rajkovic, Radmila Novakovic, Javad Sharifi‐Rad, Daniela Calina   +4 more
wiley   +1 more source

Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence

Medicina
Diabetic kidney disease (DKD) remains a major cause of advanced chronic kidney disease (CKD) and cardiovascular (CV) mortality, despite optimization of renin–angiotensin–aldosterone system (RAAS) blockade and the use of sodium–glucose cotransporter-2 ...
Adina Braha, Bogdan Timar, Adrian Sturza, Romulus Timar   +3 more
doaj   +1 more source

The Binding of Fibroblast Growth Factor 23 (FGF23) to FGF Receptor‐αKlotho Complex Increases Sinoatrial Electrical Activity

Acta Physiologica, Volume 242, Issue 10, October 2026.
ABSTRACT Aim This study aims to investigate whether the Fibroblast Growth Factor 23 (FGF23) modulates the electrical activity of sinoatrial (SAN) cells. The canonical function of FGF23 is to regulate body phosphorus and calcium homeostasis by activating the FGF1 receptors (FGFR1)/α‐Klotho complex in the kidney and parathyroid glands.
Giorgia Bertoli, Patrizia Benzoni, Serena Canzolino, David Molla, Raffaella Milanesi, Chiara Piantoni, Makoto Kuro‐o, Carmen Delgado, Gema Ruiz‐Hurtado, Mirko Baruscotti, Annalisa Bucchi   +10 more
wiley   +1 more source

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9573-9583, October 2026.
ABSTRACT Aims An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication.
Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J. Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, Luke Sheridan Rains, Amanda I. Adler, Lesley Owen   +12 more
wiley   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8757-8768, October 2026.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8812-8824, October 2026.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9412-9422, October 2026.
ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink, Gozewijn D. Laverman, Hiddo J. L. Heerspink   +2 more
wiley   +1 more source

Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways

Frontiers in Pharmacology
IntroductionInflammation is a key driver of adverse outcomes in acute myocardial infarction (AMI), yet current western anti-inflammatory therapies are limited by their single-target nature and side effects.
Chenglong Guo, Tianxing Zhang, Lingqian He, Minyu Zhang, Yanyan Chu, Xipeng Sun, Xuexue Han, Yijiang Liu, Juexian Song, Jinggang Xia   +9 more
doaj   +1 more source

Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE‐RWD)

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9461-9472, October 2026.
ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez, Antonio Tejera‐Muñoz, Patricia Tomás‐Gómez, Federico Vázquez‐San Miguel, Virginia Soria‐Utrilla, Ada María Roldán‐Sánchez, Maya Sánchez‐Baya, Jersy Cárdenas‐Salas, Blanca Timón‐Vázquez, Juan J. Gorgojo‐Martínez, Ines Modrego‐Pardo, Irea Fernández‐Xove, Jose Carlos Fernández‐García, Rebeca Reyes‐García   +13 more
wiley   +1 more source

Musa cavendish ameliorates isoproterenol-induced renal and hepatic injury in Wistar rats

Orapuh Journal
Introduction Isoproterenol (ISP) treatment is an established model for inducing myocardial infarction (MI). In acute MI, compromised renal function may result from preexisting kidney disease, acute renal failure, or the effects of pharmaceuticals and
Emuesiri Kohworho Umukoro, Erhiori Akponah, Oghenekparobor Blessing Elijah, Emuesiri Goodies Moke, John O. Ohaju-Obodo, Abraham Georgewill   +5 more
doaj   +1 more source